[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Foukas AF, Deshmukh NS, Grimer RJ, Mangham DC, Mangos EG, Taylor S: Stage-IIB osteosarcomas around the knee. A study of MMP-9 in surviving tumour cells. J Bone Joint Surg Br; 2002 Jul;84(5):706-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage-IIB osteosarcomas around the knee. A study of MMP-9 in surviving tumour cells.
  • We studied 55 patients with stage-IIB osteosarcoma around the knee with respect to the expression of matrix metalloproteinase (MMP)-9 in the surviving tumour cells in surgical resection specimens.
  • The percentage of necrosis after chemotherapy failed marginally to reach statistical significance.
  • [MeSH-major] Bone Neoplasms / metabolism. Femoral Neoplasms / metabolism. Matrix Metalloproteinase 9 / metabolism. Osteosarcoma / metabolism. Tibia

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12188489.001).
  • [ISSN] 0301-620X
  • [Journal-full-title] The Journal of bone and joint surgery. British volume
  • [ISO-abbreviation] J Bone Joint Surg Br
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.1.3.1 / Alkaline Phosphatase; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


2. Yu XC, Xu M, Song RX, Xu SF: Marginal resection for osteosarcoma with effective preoperative chemotherapy. Orthop Surg; 2009 Aug;1(3):196-202
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marginal resection for osteosarcoma with effective preoperative chemotherapy.
  • OBJECTIVE: To present the clinical results of marginal resection with effective preoperative chemotherapy for treatment of osteosarcoma.
  • METHODS: Thirty-eight patients (20 male and 18 female, average age 17 years), underwent marginal resection after confirmation of effective preoperative chemotherapy between 1999 and 2008 and the results were analyzed retrospectively.
  • The distal femur was involved in 22 cases, proximal tibia in 11, proximal humerus in 4, and proximal fibula in 1.
  • Thirty-seven patients were stage IIB and one IIIB.
  • RESULTS: All patients received effective preoperative chemotherapy.
  • At a median follow-up of 52 months, local recurrence had developed in one patient (2.6% local recurrence rate).
  • Pulmonary metastases developed in 9 patients (23.7%).
  • Five patients died of metastases, one died of intracranial hemorrhage due to thrombocytopenia caused by postoperative chemotherapy.
  • CONCLUSIONS: With careful preoperative evaluation and effective preoperative chemotherapy marginal resection of osteosarcoma can produce good results.
  • Marginal resection of osteosarcoma should be performed by an experienced surgeon who is familiar with the limb salvage rules for osteosarcoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / surgery. Orthopedic Procedures / methods. Osteosarcoma / surgery. Preoperative Care / methods
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. China / epidemiology. Disease-Free Survival. Female. Femur. Fibula. Follow-Up Studies. Humans. Humerus. Male. Prognosis. Retrospective Studies. Survival Rate / trends. Tibia. Time Factors

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 Tianjin Hospital and Blackwell Publishing Asia Pty Ltd.
  • (PMID = 22009842.001).
  • [ISSN] 1757-7861
  • [Journal-full-title] Orthopaedic surgery
  • [ISO-abbreviation] Orthop Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


3. Bertoni F, Bacchini P, Staals EL, Davidovitz P: Dedifferentiated parosteal osteosarcoma: the experience of the Rizzoli Institute. Cancer; 2005 Jun 1;103(11):2373-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated parosteal osteosarcoma: the experience of the Rizzoli Institute.
  • BACKGROUND: Dedifferentiated parosteal osteosarcoma (DPOS) is a variant of osteosarcoma in which a high-grade sarcoma coexists with a conventional parosteal osteosarcoma (c-POS), either at presentation (synchronous type) or at the time of recurrence (metachronous type).
  • METHODS: In a series of 120 patients with parosteal osteosarcoma who were seen at the Rizzoli Institute from 1958 to 2000, the authors identified 29 patients who were diagnosed with DPOS.
  • The authors reviewed the clinical and radiologic features, histologic sections, treatments, and outcomes in this group of patients with DPOS.
  • Histologically, the dedifferentiated component was high-grade osteoblastic osteosarcoma in 14 patients, fibroblastic osteosarcoma in 10 patients, giant cell-rich osteosarcoma in 3 patients, and chondroblastic osteosarcoma in 2 patients.
  • All tumors were Stage IIB, and invasion of the medullary canal was detected in 19 patients (65%).
  • Twenty-eight patients underwent surgery, and 18 of those patients received chemotherapy (5 patients received neoadjuvant chemotherapy, and 13 patients received adjuvant).
  • Of the nine patients who died, one patient received no treatment, five patients underwent surgery (with three patients achieving adequate margins) in combination with chemotherapy, and three patients underwent surgery only (with adequate margins achieved).
  • Of the 20 patients who remained alive, 13 patients underwent surgery (with 10 patients achieving adequate margins) in combination with chemotherapy, whereas 7 patients underwent surgery only (all with adequate margins).
  • [MeSH-major] Bone Neoplasms / pathology. Cell Differentiation. Osteosarcoma, Juxtacortical / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15852358.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


Advertisement
4. Ham SJ, Kroon HM, Schraffordt Koops H, Hoekstra HJ: [Poor prognosis of osteosarcoma of pelvis; 39 years of registration by the Netherlands Commission on Bone Tumors]. Ned Tijdschr Geneeskd; 2000 Jan 15;144(3):121-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Poor prognosis of osteosarcoma of pelvis; 39 years of registration by the Netherlands Commission on Bone Tumors].
  • OBJECTIVE: To evaluate the results of treatment in patients with osteosarcoma of the pelvis.
  • PATIENTS AND METHODS: Sixty-five patients with pelvic osteosarcoma registered in the files of the Netherlands Committee on Bone Tumours over 1957-1995 were reviewed.
  • Distant metastases were present in 11 patients (stage IIIB; 18%), while 50 patients had stage IIB osteosarcoma (81%) and 1 patient stage IB osteosarcoma (2%).
  • The results of treatment and survival were determined.
  • Distant metastases developed in 27 of 42 (64%) patients with curatively treated stage IIB osteosarcoma, with prolonged metastasis-free survival after chemotherapy treatment (p < 0.0012).
  • Survival in patients with stage IIB pelvic osteosarcoma was better after surgical resection of the primary tumour than after no operation (p < 0.0054); (neo)adjuvant chemotherapy gave no longer survival than surgery alone (p < 0.083).
  • CONCLUSION: The prognosis of pelvic osteosarcoma was poor, despite modern multimodality treatment regimens, including surgical resection and chemotherapy.
  • [MeSH-major] Bone Neoplasms / mortality. Bone Neoplasms / therapy. Osteosarcoma / mortality. Osteosarcoma / therapy. Pelvic Bones
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Netherlands / epidemiology. Prognosis. Registries / statistics & numerical data. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10674118.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] NETHERLANDS
  •  go-up   go-down


5. Arpaci F, Ataergin S, Ozet A, Erler K, Basbozkurt M, Ozcan A, Komurcu S, Ozturk B, Celasun B, Kilic S, Kuzhan O: The feasibility of neoadjuvant high-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with nonmetastatic high grade localized osteosarcoma: results of a phase II study. Cancer; 2005 Sep 1;104(5):1058-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The feasibility of neoadjuvant high-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with nonmetastatic high grade localized osteosarcoma: results of a phase II study.
  • BACKGROUND: The primary and secondary objectives of the current study were to improve the > or = 90% tumor necrosis rate and assess the toxicity profile of the neoadjuvant high-dose chemotherapy (HDC) regimen, respectively.
  • METHODS: Twenty-two patients with AJCC Stage IIB high-grade osteosarcoma were included in the current study.
  • Two cycles of an induction chemotherapy regimen including cisplatin, doxorubicin, and ifosfamide followed by HDC and autologous peripheral blood stem cell support or transplantation (APBSCT) were given.
  • After engraftment was achieved, the patients underwent limb-sparing surgery (LSS) followed by three to six cycles of postoperative chemotherapy depending on the tumor necrosis rate.
  • RESULTS: The median follow-up, the total duration of treatment, and the time to surgery were 23.7 months, 5.96 months, and 3.03 months, respectively.
  • At the time of last follow-up, no patient had died of chemotherapeutic toxicity.
  • CONCLUSIONS: The results of the current Phase II study suggest that neoadjuvant HDC provides a greater than 90% necrosis rate with acceptable toxicity.
  • A short duration of therapy and the feasibility of LSS in all patients are additional advantages of this approach.
  • [MeSH-major] Bone Neoplasms / therapy. Osteosarcoma / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / adverse effects. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Male. Necrosis. Neoadjuvant Therapy. Postoperative Complications. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15999369.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Ham SJ, Kroon HM, Koops HS, Hoekstra HJ: Osteosarcoma of the pelvis--oncological results of 40 patients registered by The Netherlands Committee on Bone Tumours. Eur J Surg Oncol; 2000 Feb;26(1):53-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma of the pelvis--oncological results of 40 patients registered by The Netherlands Committee on Bone Tumours.
  • AIM AND METHODS: We reviewed the oncological outcome in 40 consecutive patients with an osteosarcoma of the pelvic region, registered in the files of the Netherlands Committee on Bone Tumours (NCBT) between 1978 and 1995.
  • RESULTS: Six patients had distant metastases at initial presentation (Enneking stage IIIB), 33 patients had stage IIB osteosarcoma and one patient stage IB osteosarcoma.
  • Patients with metastases were treated with chemotherapy (four) or palliative procedures (two).
  • Patients with non-metastatic osteosarcoma were treated with surgical procedures with (14) or without (four) neoadjuvant chemotherapy, chemotherapy without surgical resection (nine), or palliative procedures (seven).
  • The median survival of stage IIB and IIIB osteosarcoma was 14 months (2-175) and 7.5 months (2-16), respectively.
  • Survival in patients with stage IIB osteosarcoma treated with curative procedures was significantly better (P<0.0006) compared with stage IIB patients treated with palliative intent.
  • Two and 5-year survival for patients with curatively treated stage IIB osteosarcoma was 35% and 26%, respectively; distant metastases had developed in 65% of these patients.
  • On univariate analysis, positive prognostic factors for patients with stage IIB osteosarcoma were complaints of 3 months or less before initial presentation, tumour size of 8 cm or less, osteoblastic subtype, surgical resection of the primary tumour and limb salvage procedures.
  • CONCLUSION: In conclusion, the prognosis of pelvic osteosarcoma remained poor despite modern multimodality treatment regimens, including neoadjuvant chemotherapy.
  • [MeSH-major] Bone Neoplasms / therapy. Osteosarcoma / therapy. Pelvic Bones
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Hemipelvectomy. Humans. Male. Middle Aged. Neoplasm Staging. Netherlands. Prognosis. Registries. Retrospective Studies. Risk Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10718181.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


7. Hayashi K, Tsuchiya H, Yamamoto N, Takeuchi A, Tomita K: Functional outcome in patients with osteosarcoma around the knee joint treated by minimised surgery. Int Orthop; 2008 Feb;32(1):63-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional outcome in patients with osteosarcoma around the knee joint treated by minimised surgery.
  • The functional results of prostheses and osteoarticular grafts for osteosarcoma around the knee joint are not satisfactory because of poor durability and gross distortion of the normal anatomy.
  • We have investigated the functional outcome of intentional marginal excision for osteosarcoma around the knee joint in conjunction with caffeine-potentiated chemotherapy.
  • Twenty-one patients with AJCC stage IIB high-grade osteosarcoma around the knee joint were given three to five preoperative courses of intra-arterial cisplatin and caffeine with or without doxorubicin.
  • The histological response in these 21 patients to preoperative chemotherapy was grade IV (no viable cells) in 19 patients and grade III (only scattered foci of viable cells) in 2.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / surgery. Caffeine / therapeutic use. Knee Joint / surgery. Osteosarcoma / surgery. Osteotomy / methods. Phosphodiesterase Inhibitors / therapeutic use. Premedication
  • [MeSH-minor] Adolescent. Adult. Child. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Neoadjuvant Therapy. Osteogenesis, Distraction. Recovery of Function. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Caffeine.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CAFFEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Br. 2002 Jan;84(1):88-92 [11837839.001]
  • [Cites] J Bone Joint Surg Br. 2002 Nov;84(8):1162-6 [12463663.001]
  • [Cites] J Orthop Sci. 2003;8(3):374-80 [12768481.001]
  • [Cites] J Bone Joint Surg Am. 1986 Dec;68(9):1331-7 [3465732.001]
  • [Cites] Clin Orthop Relat Res. 1993 Jan;(286):241-6 [8425352.001]
  • [Cites] J Bone Joint Surg Br. 1994 Jan;76(1):127-32 [8300655.001]
  • [Cites] Pediatr Radiol. 2000 May;30(5):289-98 [10836589.001]
  • [Cites] Clin Orthop Relat Res. 1999 Jan;(358):27-35 [9973973.001]
  • [Cites] Clin Orthop Relat Res. 1999 Jan;(358):111-9 [9973982.001]
  • [Cites] Arch Orthop Trauma Surg. 1999;119(5-6):327-31 [10447633.001]
  • [Cites] J Bone Joint Surg Am. 2004 Dec;86-A(12):2686-93 [15590854.001]
  • [Cites] Cancer. 2005 Sep 1;104(5):1058-65 [15999369.001]
  • [Cites] Int Orthop. 1998;22(5):330-4 [9914940.001]
  • (PMID = 18214479.001).
  • [ISSN] 0341-2695
  • [Journal-full-title] International orthopaedics
  • [ISO-abbreviation] Int Orthop
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Phosphodiesterase Inhibitors; 3G6A5W338E / Caffeine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2219930
  •  go-up   go-down


8. Abe S, Tateishi A, Ogawa K, Ganev GG, Nakano H: Long-term local intensive preoperative chemotherapy and joint-preserving conservative surgery for osteosarcoma around the knee. Orthopedics; 2001 Jul;24(7):671-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term local intensive preoperative chemotherapy and joint-preserving conservative surgery for osteosarcoma around the knee.
  • This study evaluated conservative joint-sparing surgery for patients with osteosarcoma around the knee.
  • Of 23 patients with stage IIB osteosarcoma around the knee, 5 were treated with long-term (30-56 weeks) local intensive preoperative chemotherapy consisting of high-dose methotrexate, intra-arterial and intravenous cisplatinum, doxorubicin, and hyperthermic isolated regional perfusion.
  • These results suggest long-term local intensive preoperative chemotherapy, including intra-arterial cisplatin and hyperthermic isolated regional perfusion, help control local tumor and allow for more conservative surgery.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / surgery. Chemotherapy, Cancer, Regional Perfusion / methods. Femoral Neoplasms / drug therapy. Femoral Neoplasms / surgery. Hyperthermia, Induced / methods. Knee Joint. Osteosarcoma / drug therapy. Osteosarcoma / surgery. Osteotomy / methods. Preoperative Care / methods. Tibia
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant / methods. Chemotherapy, Adjuvant / standards. Cisplatin / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Infusions, Intravenous. Injections, Intra-Arterial. Male. Methotrexate / administration & dosage. Neoplasm Staging. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11478554.001).
  • [ISSN] 0147-7447
  • [Journal-full-title] Orthopedics
  • [ISO-abbreviation] Orthopedics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


9. Charity RM, Foukas AF, Deshmukh NS, Grimer RJ: Vascular endothelial growth factor expression in osteosarcoma. Clin Orthop Relat Res; 2006 Jul;448:193-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor expression in osteosarcoma.
  • Vascular endothelial growth factor expression by osteosarcomas at biopsy has been shown to have a negative influence on survival.
  • Whether it continues to be expressed and influence outcome in tumors after neoadjuvant chemotherapy has not been determined.
  • To determine if a high-degree of vascular endothelial growth factor expression by the surviving osteosarcoma cells in the resected tumor has a negative influence on prognosis, we retrospectively reviewed 52 patients with Stage IIB osteosarcoma around the knee, 48 of whom received neoadjuvant chemotherapy.
  • LEVEL OF EVIDENCE: Prognostic study, Level II (retrospective study).
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Bone Neoplasms / metabolism. Osteosarcoma / metabolism. Vascular Endothelial Growth Factor A / biosynthesis


10. Machak GN, Kochergina NV, Sen'ko OV, Kuznetsova AV: [The role of clinical and imaging criteria in risk assessment during preoperative chemotherapy for osteosarcoma]. Vopr Onkol; 2005;51(3):322-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of clinical and imaging criteria in risk assessment during preoperative chemotherapy for osteosarcoma].
  • Prognosis for stage IIB osteosarcoma was evaluated versus the role of preoperative management of clinico-radiologic status in 293 patients.
  • Clinico-radiologic status was assessed in the course of preoperative chemotherapy.
  • One hundred fifty patients were alive at the last examination, 139 had died of tumor progression, and 4 - chemotherapy complication.
  • The two courses of preoperative chemotherapy were followed by more favorable outcome.
  • Complete clinical response, tumors downsized to 300 mm, intra-osseous healing, periosteal assimilation and margination of extra-osseous masses had a significant positive impact on disease-free survival in the chemotherapy group.
  • Clinico-radiologic status monitoring in the course of preoperative chemotherapy is instrumental in predicting risks as well as designing alternative strategies of treatment at earlier stages.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / diagnosis. Bone Neoplasms / drug therapy. Osteosarcoma / diagnosis. Osteosarcoma / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Infusions, Intra-Arterial. Male. Neoadjuvant Therapy. Prognosis. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16279096.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Kim MS, Cho WH, Song WS, Lee SY, Jeon DG: time dependency of prognostic factors in patients with stage II osteosarcomas. Clin Orthop Relat Res; 2007 Oct;463:157-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] time dependency of prognostic factors in patients with stage II osteosarcomas.
  • Although several clinicopathologic parameters may be related to metastasis-free survival in osteosarcoma, the importance of prognostic factors with time is largely unknown.
  • Therefore, we asked whether the clinical characteristics of patients with osteosarcoma with metastasis after 2 years differed from those of patients with an earlier metastatic event.
  • We retrospectively reviewed 420 patients with Stage IIB osteosarcoma treated with surgery and chemotherapy.
  • Histologic response and chondroblastic subtype showed time-related changes.
  • [MeSH-major] Bone Neoplasms / diagnosis. Osteosarcoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Femur / pathology. Femur / surgery. Humans. Male. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Tibia / pathology. Tibia / surgery. Time Factors

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17621233.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Thompson RC Jr, Cheng EY, Clohisy DR, Perentesis J, Manivel C, Le CT: Results of treatment for metastatic osteosarcoma with neoadjuvant chemotherapy and surgery. Clin Orthop Relat Res; 2002 Apr;(397):240-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of treatment for metastatic osteosarcoma with neoadjuvant chemotherapy and surgery.
  • The purpose of the current study was to define the survival outcome variables for the 85 patients with Stage IIB osteosarcoma treated with neoadjuvant chemotherapy at the authors' institution from 1982 to 1997.
  • The mean time to metastasis after diagnosis for patients presenting with Stage IIB disease was 12.8 months.
  • There was no difference in the survival for any of the three chemotherapy protocols, used during the 15 years included in this analysis.
  • There was a significant relation between length of time to relapse and survival.
  • A favorable outcome in this cohort of patients is related to the length of time between initiation of therapy and diagnosis of metastasis, and the number of metastatic foci.
  • [MeSH-major] Bone Neoplasms / mortality. Bone Neoplasms / surgery. Lung Neoplasms / secondary. Osteosarcoma / mortality. Osteosarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Child, Preschool. Humans. Life Tables. Middle Aged. Retrospective Studies. Survival Analysis. Thoracotomy. Treatment Outcome


13. Kim MS, Song WS, Cho WH, Lee SY, Jeon DG: Ezrin expression predicts survival in stage IIB osteosarcomas. Clin Orthop Relat Res; 2007 Jun;459:229-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ezrin expression predicts survival in stage IIB osteosarcomas.
  • We analyzed the relationship between immunohistochemical expression of ezrin and the prognosis of osteosarcoma.
  • We retrospectively identified 64 patients with Stage IIB osteosarcomas between 1995 and 2000.
  • Tissue microarrays were constructed from incisional biopsy specimens and immunohistochemical staining was performed.
  • Multivariate analysis revealed histologic response to preoperative chemotherapy and expression of ezrin predicted disease-free survival.
  • Expression of ezrin in osteosarcoma biopsy specimens is promising as a marker to predict outcome in patients with osteosarcoma.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Bone Neoplasms / metabolism. Bone Neoplasms / pathology. Cytoskeletal Proteins / metabolism. Osteosarcoma / metabolism. Osteosarcoma / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353802.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytoskeletal Proteins; 0 / ezrin
  •  go-up   go-down


14. Guo W, Yang RL, Tang XD, Tang S, Li DS, Yang Y: [Neoadjuvant chemotherapy for osteosarcoma]. Zhonghua Yi Xue Za Zhi; 2004 Jul 17;84(14):1186-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neoadjuvant chemotherapy for osteosarcoma].
  • OBJECTIVE: To summarize the experience in neoadjuvant chemotherapy for osteosarcoma.
  • METHODS: Between July 1996 and December 2002 113 patients, 65 males and 48 females, aged 7 approximately 31, with osteosarcoma located in pelvis (n = 2), sacrum (n = 1), proximal femur (n = 6), shaft of femur (n = 4), distal femur (n = 49), proximal tibia (n = 37), shaft of tibia (n = 2), distal tibia (n = 1), fibula (n = 3), scapula (n = 1), clavicle (n = 1), or proximal humerus, (n = 7) without metastasis, 7 of which being at the Ennecking stage of IIA and 106 of which being at the stage of IIB, underwent 2 cycles of chemotherapy with high dose methotrexate (MTX) preoperatively and then operation.
  • If poor response was observed after the first cycle of chemotherapy MTX was abandoned and operation was performed immediately.
  • At least 3 cycles of chemotherapy were given postoperatively for all patients.
  • RESULTS: Sixty patients showed excellent response to the preoperative chemotherapy, 35 showed good response, and 18 showed poor response.
  • CONCLUSION: The neoadjuvant chemotherapy protocol with the second-line drugs such as ifosfamide and paclitaxel used to the patients responding poorly to MTX is more effective than the older protocol.
  • Local arterial chemotherapy is feasible.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Neoadjuvant Therapy. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Cisplatin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Femoral Neoplasms / drug therapy. Femoral Neoplasms / pathology. Femoral Neoplasms / surgery. Humans. Ifosfamide / administration & dosage. Male. Retrospective Studies

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15387981.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


15. Kudawara I, Ieguchi M, Aoki Y, Naka N, Araki N, Nakanishi H, Matsumine A, Myoui A, Ueda T, Yoshikawa H: Neoadjuvant chemotherapy with high-dose ifosfamide, doxorubicin and cisplatin in nonmetastatic osteosarcoma of the extremity. J Clin Oncol; 2004 Jul 15;22(14_suppl):9039

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy with high-dose ifosfamide, doxorubicin and cisplatin in nonmetastatic osteosarcoma of the extremity.
  • : 9039 Background: Doxorubicin (DOX), cisplatin (CDDP) and methotrexate (MTX) are active agents for the treatment of osteosarcoma (OS).
  • Neoadjuvant chemotherapy including these multi-agents has been established.
  • However, ifosfamide (IFM) is mainly used in poor responders to adjuvant chemotherapy.
  • PATIENTS AND METHODS: From 1997 to 2000, 26 patients (pts) with newly diagnosed, previously untreated nonmetastatic (stage IIB) OS of extremities received the OOS-D protocol.
  • Local wide excision was scheduled after 4 courses of chemotherapy.
  • Two cycles of postoperative chemotherapy consisted of DOX + CDDP, IFM and HD-MTX (10-12 g/m2).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013724.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Pallotta MG, Specterman S, Gioseffi H, Lopez Lincuez ME, Beguelin GZ, Lastiri JM, Varela MS, Makiya M, Dibar E, Muscolo DL: Tumor size as prognostic factor in osteosarcomas. J Clin Oncol; 2004 Jul 15;22(14_suppl):9061

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor size as prognostic factor in osteosarcomas.
  • : 9061 Background: Multidisciplinary treatment of osteosarcoma has achieved overall survival greater than 70%.
  • In order to assess the relation between tumor size and prognosis in high-grade osteosarcoma, we performed the following analysis.
  • METHODS: Retrospectively, tumor volume was determined pre and post chemotherapy in 40 patients with histological diagnosis of high-grade osteosarcoma stage IIb.
  • All of them received neo-adjuvant chemotherapy (ifosfamide + doxorrubicin + high dose methotrexate).
  • Tumor volume pre chemotherapy greater than >1500 cm3 (MRI) was the variable most predictor of mortality (p=0.02).
  • Intensification of radiological calcification, pathological fracture and changes in size pre and post chemotherapy did not have prognostic value.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014082.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Liu YS, Li DF, Liu SB, Cui Q: [Intraarterial neoadjuvant chemotherapy for extremity osteosarcoma]. Zhonghua Yi Xue Za Zhi; 2009 Nov 10;89(41):2915-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraarterial neoadjuvant chemotherapy for extremity osteosarcoma].
  • OBJECTIVE: To summarize the experiences in intraarterial neoadjuvant chemotherapy for extremity osteosarcoma.
  • METHODS: Between January 2002 and December 2007, 111 patients with stage IIB extremity osteosarcoma received preoperative intraarterial chemotherapy after placing chemotherapy pump subcutaneously, en bloc resection and postoperative adjuvant chemotherapy.
  • The time from symptom onset to hospitalization varied from several days to 6 months.
  • The induction chemotherapy regimen included epirubicin [50 - 70 mg/m(2) by 4-hour intraarterial infusion/day for 3 days] and epirubicin plus adriamycin [100 - 120 mg/m(2) by 2-hour intraarterial infusion/day for 3 days] repetitively every 2 - 3 weeks.
  • Among which 24 cases only received 2 cycles of induction chemotherapy was assigned into the nonstandard chemotherapy group and 87 cases receiving 3 - 6 cycles of induction chemotherapy the standard chemotherapy group.
  • The number of preoperative chemotherapeutical cycles of standard chemotherapy group depended on the clinical and radiographic evaluation of chemotherapy efficacy.
  • RESULTS: The median follow-up time was 28 (8 - 48) months.
  • The rate of extremity preservation surgery was 89.53% (77/86) in the standard chemotherapy group and 37.5% (9/24) in the nonstandard chemotherapy group.
  • CONCLUSION: Standard intraarterial neo-adjuvant chemotherapy is more effective than nonstandard intraarterial induction chemotherapy to treat stage IIB extremity osteosarcoma.
  • [MeSH-major] Catheters, Indwelling. Chemotherapy, Adjuvant. Neoadjuvant Therapy. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Brachial Artery. Disease-Free Survival. Doxorubicin / therapeutic use. Epirubicin / therapeutic use. Extremities. Female. Femoral Artery. Humans. Iliac Artery. Male. Subclavian Artery. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Osteosarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20137649.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 80168379AG / Doxorubicin
  •  go-up   go-down


18. Kanazawa Y, Tsuchiya H, Nonomura A, Takazawa K, Yamamoto N, Tomita K: Intentional marginal excision of osteosarcoma of the proximal fibula to preserve limb function. J Orthop Sci; 2003;8(6):757-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intentional marginal excision of osteosarcoma of the proximal fibula to preserve limb function.
  • Three cases of osteosarcoma (stage IIB) of the proximal fibula were successfully treated by marginal excision that preserved the common peroneal nerve and lateral stabilizers of the knee joint.
  • Caffeine-assisted chemotherapy was administered to three boys, ages 15, 17, and 11 years, and resulted in a complete response.
  • Two patients initially presented with peroneal nerve palsy that resolved completely with preoperative chemotherapy.
  • For patients with osteosarcoma of the proximal fibula, this approach provides a better quality of life than conventional wide excision.
  • [MeSH-major] Bone Neoplasms / surgery. Fibula / surgery. Orthopedic Procedures / methods. Osteosarcoma / surgery
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Chemotherapy, Adjuvant. Child. Combined Modality Therapy / methods. Follow-Up Studies. Humans. Male. Neoplasm Staging. Preoperative Care / methods. Recovery of Function. Risk Assessment. Sampling Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14648261.001).
  • [ISSN] 0949-2658
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Guo W, Tang XD, Liu J, Yang Y: [Evaluation of neoadjuvant chemotherapy for patients with stage II osteosarcoma]. Zhonghua Wai Ke Za Zhi; 2009 Nov 1;47(21):1634-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of neoadjuvant chemotherapy for patients with stage II osteosarcoma].
  • OBJECTIVE: To retrospectively review the effect of chemotherapy and survival rate of osteosarcoma in extremity.
  • METHODS: Between July 1997 and July 2007, 296 patients with osteosarcoma received neo-adjuvant chemotherapy and surgery.
  • The tumors located in proximal femur in 10 patients, diaphyseal of femur in 7, distal femur in 148, proximal tibia in 80, distal tibia in 5, fibula in 11, humerus in 33, and distal radius in 2 patients.
  • According to Enneking stage system, 6 patients were in stage IIA and others in stage IIB.
  • All patients received evaluation of preoperative chemotherapy, and 72 patients had analysis of tumor necrosis after operation.
  • RESULTS: After mean follow-up of 47 months, metastasis developed in 98 (33.1%) patients.
  • The metastatic rate was 15.5%, 31.0%, and 77.1% in patients with substantial effective chemotherapy, partial effective chemotherapy, and no effective chemotherapy, respectively.
  • In tumor necrosis analysis, reduction of tumor volume and more clear margin after preoperative chemotherapy were related to higher tumor necrosis.
  • CONCLUSIONS: The patients with osteosarcoma should receive chemotherapy as soon as possible.
  • More effective chemotherapy means lower metastatic rate and higher no event survival rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Extremities. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20137398.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


20. Kim MS, Lee SY, Cho WH, Song WS, Koh JS, Lee JA, Yoo JY, Jung ST, Jeon DG: Effect of increases in tumor volume after neoadjuvant chemotherapy on the outcome of stage II osteosarcoma regardless of histological response. J Orthop Sci; 2009 May;14(3):292-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of increases in tumor volume after neoadjuvant chemotherapy on the outcome of stage II osteosarcoma regardless of histological response.
  • BACKGROUND: We assessed volume changes after neoadjuvant chemotherapy and evaluated relations between tumor size changes and clinical characteristics.
  • METHODS: The records of 127 patients with stage II osteosarcoma who showed more than a 15% volume change after chemotherapy were retrospectively reviewed.
  • An increase in tumor volume after neoadjuvant chemotherapy was found to be positively correlated with a poor histological response and subsequent metastasis.
  • Univariate analysis identified the following parameters as poor prognostic factors: age < or = 15 years (P = 0.03), American Joint Committee on Cancer (AJCC) stage IIB (P = 0.02), a subtype other than osteoblastic (P < 0.01), a poor histological response (P < 0.001), and increased tumor volume after preoperative chemotherapy (P < 0.0001).
  • Multivariate analysis revealed that AJCC stage IIB (P = 0.006) and an increase in tumor volume after preoperative chemotherapy (P < 0.001) both independently shortened metastasis-free survival.
  • CONCLUSIONS: Increased tumor volume after neoadjuvant chemotherapy independently shortened metastasis-free and overall survival in AJCC stage II osteosarcoma patients.
  • Tumor volume changes may serve as a basis for risk-adapted therapy when used in combination with other prognostic factors.
  • [MeSH-major] Drug Resistance, Neoplasm. Neoadjuvant Therapy. Osteosarcoma / drug therapy. Osteosarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Neoplasm Metastasis. Prognosis. Retrospective Studies. Risk. Young Adult

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19499296.001).
  • [ISSN] 1436-2023
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


21. Hayashi K, Tsuchiya H, Yamamoto N, Shirai T, Yamauchi K, Takeuchi A, Kawahara M, Miyamoto K, Tomita K: Impact of serum caffeine monitoring on adverse effects and chemotherapeutic responses to caffeine-potentiated chemotherapy for osteosarcoma. J Orthop Sci; 2009 May;14(3):253-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of serum caffeine monitoring on adverse effects and chemotherapeutic responses to caffeine-potentiated chemotherapy for osteosarcoma.
  • BACKGROUND: Caffeine can safely enhance the cytocidal effects of anticancer drugs through its DNA repair-inhibiting effect.
  • We have demonstrated in several studies that caffeine-potentiated chemotherapy induces a high complete response rate in patients with osteosarcoma.
  • The present study focused on monitoring and adjusting serum caffeine levels during caffeine-potentiated chemotherapy to reduce adverse effects.
  • The study involved 22 American Joint Committee on Cancer (AJCC) stage IIB high-grade osteosarcoma patients treated with caffeine-potentiated chemotherapy.
  • Histological examination of excised tumor samples after preoperative chemotherapy revealed that chemotherapeutic efficacy in the monitoring group was as good as in the nonmonitoring group.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Caffeine / blood. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Biomarkers / blood. Child. Child, Preschool. Cisplatin / administration & dosage. Cisplatin / adverse effects. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Drug Synergism. Female. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Caffeine.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CAFFEINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19499290.001).
  • [ISSN] 1436-2023
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; 3G6A5W338E / Caffeine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


22. Kim MS, Lee SY, Lee TR, Cho WH, Song WS, Koh JS, Lee JA, Yoo JY, Jeon DG: Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma. Ann Oncol; 2009 May;20(5):955-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma.
  • BACKGROUND: In this retrospective study, we developed and internally validate a nomogram for predicting 5-year metastasis probability for nonmetastatic extremity osteosarcoma.
  • PATIENTS AND METHODS: We reviewed 365 osteosarcoma patients treated at our institute from 1990 to 2003.
  • RESULTS: By American Joint Committee on Cancer (AJCC) staging system, 141 patients (38.6%) were stage IIA and 224 (61.4%) were stage IIB.
  • Multivariate Cox model identified patient age at diagnosis, tumor size, humeral location, and tumor necrosis rate after chemotherapy as correlated with metastasis-free survival.
  • Nomogram discrimination was superior to that of AJCC stage (concordance index 0.78 versus 0.68; P = 0.02) and histologic response grouping (concordance index 0.78 versus 0.69; P = 0.0004).
  • CONCLUSIONS: We devised a nomogram for nonmetastatic osteosarcoma that proposes improved estimates of metastasis over AJCC staging system or tumor necrosis rate.
  • We suggest that this nomogram allows individualized risk assessments and could be used as the basis for risk-adapted therapy.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19153123.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


23. Tunn PU, Reichardt P: Chemotherapy for osteosarcoma without high-dose methotrexate: a 12-year follow-up on 53 patients. Onkologie; 2007 May;30(5):228-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for osteosarcoma without high-dose methotrexate: a 12-year follow-up on 53 patients.
  • BACKGROUND: The clinical relevance of polychemotherapy in osteosarcoma is undisputed and well proven.
  • In this retrospective study we report the results of chemotherapy treatment without high-dose methotrexate (HDMTX) for osteosarcoma.
  • PATIENTS AND METHODS: Between 1986 and 1992, 53 patients with stage IIB extremity osteosarcoma received multimodal therapy (age: 6-36 years, median 17 years).
  • All patients received neoadjuvant and adjuvant chemotherapy with adriamycin, cisplatin, cyclophosphamide, and vincristine without HDMTX.
  • 35.8% of patients developed pulmonary metastases.
  • Five-year OAS was 31.6% in patients who developed pulmonary metastases.
  • Ten-year OAS was 73.5% in responders to preoperative chemotherapy; in poor responders 62.1% (p = 0.353).
  • CONCLUSION: Compared to treatment protocols including HDMTX similar survival rates were achieved.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Methotrexate / administration & dosage. Neoadjuvant Therapy. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Limb Salvage. Male. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Onkologie. 2007 May;30(5):226-7 [17460415.001]
  • (PMID = 17460416.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


24. Nozaki T, Kusuzaki K, Takeshita H, Nakamura S, Hashiguchi S, Murata H, Hirasawa Y: Effectiveness of activated vitamin D3 on improving prognosis of osteosarcoma patients. Oncol Rep; 2001 Mar-Apr;8(2):321-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of activated vitamin D3 on improving prognosis of osteosarcoma patients.
  • We examined the survival prognosis of patients with osteosarcoma after orally administering the active form of vitamin D3, 1alpha (OH) D3 (alphaD3).
  • The 29 patients, ranging in age from 9 to 58 years (mean, 19 years), with osteosarcoma were treated in our department between 1983 and 1995.
  • The surgical stage was IIB in all patients.
  • These patients underwent chemotherapy mainly with adriamycin and cisplatin, and wide tumor resection.
  • Therefore, we concluded that alphaD3 at the dose used in this study was not effective in improving the prognosis of osteosarcoma patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / surgery. Calcifediol / therapeutic use. Osteosarcoma / drug therapy. Osteosarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11182048.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 80168379AG / Doxorubicin; P6YZ13C99Q / Calcifediol; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


25. Kim MS, Lee SY, Cho WH, Song WS, Koh JS, Lee JA, Yoo JY, Shin DS, Jeon DG: Growth patterns of osteosarcoma predict patient survival. Arch Orthop Trauma Surg; 2009 Sep;129(9):1189-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth patterns of osteosarcoma predict patient survival.
  • In addition, we also evaluated the relationship between patient outcome and tumor growth pattern in the whole study cohort and in subsets of AJCC IIA and IIB patients.
  • MATERIALS AND METHODS: We retrospectively reviewed 347 patients with Enneking stage IIB and AJCC stage II osteosarcoma that was treated with surgery and neoadjuvant chemotherapy at our institute.
  • Eccentric tumors were usually small and responded well to chemotherapy, whereas concentric tumors were large and responded poorly.
  • Among AJCC stage IIA patients, no survival difference was found according to growth pattern, whereas in AJCC stage IIB patients, longitudinal tumors were associated with significantly better survival than concentric tumors.
  • CONCLUSIONS: Tumor growth pattern was found to be an independent prognostic factor in stage II osteosarcoma.
  • Moreover, longitudinally growing tumors were associated with better survival in AJCC stage IIB patients.
  • Our results suggest that tumor growth pattern could be used as an indicator of risk-adapted therapy when combined with other prognostic factors.
  • [MeSH-major] Bone Neoplasms / pathology. Osteosarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Epidemiologic Methods. Female. Humans. Magnetic Resonance Imaging / methods. Male. Neoplasm Staging / methods. Prognosis. Time Factors. Treatment Outcome. Tumor Burden. Young Adult

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18682966.001).
  • [ISSN] 1434-3916
  • [Journal-full-title] Archives of orthopaedic and trauma surgery
  • [ISO-abbreviation] Arch Orthop Trauma Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


26. Zhang Y, Yang Z, Li X, Chen Y, Zhang S, Du M, Li J: Custom prosthetic reconstruction for proximal tibial osteosarcoma with proximal tibiofibular joint involved. Surg Oncol; 2008 Aug;17(2):87-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Custom prosthetic reconstruction for proximal tibial osteosarcoma with proximal tibiofibular joint involved.
  • BACKGROUND: The therapeutic results of managing proximal tibial osteosarcoma have been dramatically improved because of the recent advancements in imaging, chemotherapy, and surgical techniques.
  • Further, the prognosis of patients with proximal tibial osteosarcoma is improved and the chance of survival with limb salvage surgery is increased.
  • However, the treatment for proximal tibial osteosarcoma with proximal tibiofibular joint involved has not been reported.
  • OBJECTIVE: The report of the preliminary results of custom prosthetic reconstruction for proximal tibial osteosarcoma with proximal tibiofibular joint involved following the primary tumor resection.
  • MATERIALS AND METHOD: Eleven patients with osteosarcoma of the proximal tibia and proximal tibiofibular joint were studied in 1995-2005, at Qilu Hospital of the Shandong University.
  • The surgical stage of all of the patients was Stage IIB, according to the Enneking Surgical Staging System.
  • After neo-adjuvant chemotherapy, all of the patients underwent en bloc resection.
  • This procedure included the proximal tibiofibular joint and the upper end of the fibula, followed by custom prosthetic replacement.
  • RESULTS: During the mean follow-up time of 47 months (range 12-96), six patients lived free of the disease, and five patients experienced various complications.
  • Several early complications had occurred amongst those five patients: one developed skin necrosis; two experienced transient palsy of the common peroneal nerve; and two developed deep vein thrombus of the lower limb.
  • CONCLUSION: Custom prosthetic reconstruction could yield as much satisfactory results as neoadjuvant chemotherapy and limb salvage surgery, for patients with osteosarcoma in proximal tibia and proximal tibiofibular joint.
  • [MeSH-major] Arthroplasty, Replacement, Knee. Bone Neoplasms / surgery. Knee Prosthesis. Osteosarcoma / surgery. Prosthesis Design. Tibia
  • [MeSH-minor] Adolescent. Adult. Cohort Studies. Female. Humans. Male. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Knee Replacement.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18160278.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


27. Guo W, Sun X, Ji T: [Evaluation of surgical treatment of pelvic osteosarcoma]. Zhonghua Wai Ke Za Zhi; 2010 Jul 1;48(13):994-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of surgical treatment of pelvic osteosarcoma].
  • OBJECTIVES: To investigate the clinical outcome of consecutive pelvic osteosarcoma treated with surgery and chemotherapy in a single institution, and to discuss the surgical strategy, resection and reconstruction.
  • METHODS: Twenty-one consecutive cases with pelvic osteosarcoma underwent surgical procedures between June 2000 and June 2009.
  • According to Enneking and Dunham pelvic classification system, type Iwas 3 cases, type I+IV 3 cases, type I+II 4 cases, type II+III 4 cases, type I+II+III 1 case, type III 1 case, and type I+II+IV 5 cases.
  • Among the 21 cases, 19 were diagnosed as classical osteosarcoma and 2 were diagnosed as low-grade pathologically.
  • All the tumors were stage IIB.
  • Two patients received hemipelvectomy and one type III patients had resection without reconstruction.
  • RESULTS: Thirteen patients out of 21 survived after treatment.
  • The local recurrence rate was 28.6%, among which 4 cases were type II resection, 1 was type I resection, 1 was type I+IV resection.No local relapse was found on the hemipelvectomy and type III resection cases.
  • CONCLUSION: Limb salvage procedures could be performed on most pelvic osteosarcoma cases, and satisfying function outcome could be achieved with proper reconstruction, however, the overall survival is still lower compared with those in extremities.
  • [MeSH-major] Bone Neoplasms / surgery. Osteosarcoma / surgery. Pelvic Bones
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Follow-Up Studies. Hemipelvectomy. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21054983.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


28. Abe S, Nishimoto Y, Isu K, Ishii T, Goto T, Japanese Musculoskeletal Oncology Group: Preoperative cisplatin for initial treatment of limb osteosarcoma: its local effect and impact on prognosis. Cancer Chemother Pharmacol; 2002 Oct;50(4):320-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative cisplatin for initial treatment of limb osteosarcoma: its local effect and impact on prognosis.
  • The purpose of this multi-institution study was to assess the local effect of preoperative CDDP as a single agent as well as its impact on the prognosis of limb osteosarcoma.
  • PATIENTS AND METHODS: The study group comprised 44 patients with stage IIB limb osteosarcoma who were treated with single-agent CDDP as initial preoperative chemotherapy.
  • Two to five courses of CDDP (mean 2.4 courses) were administered intravenously and/or intraarterially as an initial preoperative treatment.
  • The effect of the treatment was evaluated clinically and histologically.
  • The survival rate was 59.1% among all patients in the study, 64.0% among those with a grade III or IV clinical response, and 52.6% among those with a grade I or II clinical response, with no significant differences between the groups.
  • The survival rate was 70% among patients with a grade III or IV histological response, and 54.5% among those with a grade I or II histological response, with no statistical differences between the groups.
  • CONCLUSIONS: We consider that CDDP is a useful chemotherapeutic agent for preoperative induction therapy for osteosarcoma because of the excellent local effect observed.
  • Systemic multidrug chemotherapy should follow preoperative CDDP to diminish the microscopic foci of metastatic disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Extremities. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Combined Modality Therapy. Humans. Lung Neoplasms / secondary. Preoperative Care. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12357307.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


29. Kim MS, Lee SY, Cho WH, Song WS, Koh JS, Lee JA, Yoo JY, Jeon DG: Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients. Ann Surg Oncol; 2008 Mar;15(3):906-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients.
  • BACKGROUND: We assessed whether new parameter that considers both tumor volume change and necrosis rate predicts metastasis-free survival of localized osteosarcoma patients.
  • METHODS: We retrospectively reviewed 151 patients with stage II osteosarcoma who were treated with surgery and neoadjuvant chemotherapy.
  • American Joint Committee on Cancer (AJCC) stage IIB (RR 2.27; 95% CI, 1.11-4.62; P = 0.025) and poor adjusted tumor necrosis rate (RR 2.02; 95% CI, 1.05-3.89; P = 0.035) independently correlated with metastasis-free survival period.
  • CONCLUSION: The necrosis rate adjusted by the tumor volume change is an independent prognostic factor in osteosarcoma.
  • This adjusted tumor necrosis rate may serve as a basis for risk-adapted therapy in combination with other prognostic factors.
  • [MeSH-major] Bone Neoplasms / mortality. Bone Neoplasms / pathology. Bone and Bones / pathology. Osteosarcoma / mortality. Osteosarcoma / pathology. Tumor Burden

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18163171.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Todesco A, Carli M, Iacona I, Frascella E, Ninfo V, Rosolen A: All-trans retinoic acid and interferon-alpha in the treatment of a patient with resistant metastatic osteosarcoma. Cancer; 2000 Dec 15;89(12):2661-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] All-trans retinoic acid and interferon-alpha in the treatment of a patient with resistant metastatic osteosarcoma.
  • BACKGROUND: A boy age 14 years who was in complete remission from Stage IIB small cell osteosarcoma, which was misdiagnosed as Ewing sarcoma and consequently was treated, developed inoperable lung metastases when he was off therapy.
  • He received second-line treatment for recurrent Ewing sarcoma, including chemotherapy and radiotherapy, and obtained only a temporary response.
  • A compassionate treatment with all-trans retinoic acid (ATRA) and interferon-alpha (IFNalpha) was then undertaken.
  • METHODS: The patient initially was treated according to the national SE91 protocol for nonmetastatic Ewing sarcoma.
  • After a bilateral pulmonary recurrence, he received second-line chemotherapy and irradiation of the largest metastasis, with a temporary partial response.
  • The same therapy also was administered for the control of residual disease after surgery for a total duration of 1 year of ATRA/IFN treatment.
  • During the first 3 weeks of therapy, ATRA pharmacokinetics were studied.
  • RESULTS: After progression of the patient's disease, despite the administration of first-line and second-line chemotherapy, combined treatment with ATRA/IFNalpha yielded a partial remission, which allowed surgical resection of the largest metastasis.
  • The same therapy was effective in preventing tumor recurrence after incomplete removal of the remaining metastases.
  • Treatment was well tolerated, and the patient is in stable complete remission 14 months after the end of therapy.
  • The pharmacokinetics results confirmed the indication of an intermittent schedule for oral ATRA therapy.
  • CONCLUSIONS: ATRA/IFNalpha treatment may be considered as an alternative approach in the treatment of patients with metastatic osteosarcoma who have disease that is resistant to conventional chemotherapy and in the treatment of patients with minimal tumor residue.
  • [MeSH-major] Femoral Neoplasms / drug therapy. Interferon-alpha / therapeutic use. Lung Neoplasms / drug therapy. Osteosarcoma / drug therapy. Tretinoin / therapeutic use
  • [MeSH-minor] Adolescent. Drug Therapy, Combination. Humans. Lung / drug effects. Lung / pathology. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 11135229.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Interferon-alpha; 5688UTC01R / Tretinoin
  •  go-up   go-down


31. Natarajan M, Paraskumar M, Rajkumar G, Sivaseelam A, Natarajan S: Limb salvage in aggressive and malignant tumours of the fibula. Int Orthop; 2004 Oct;28(5):307-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 11 osteosarcomas, seven Ewing's sarcoma and five chondrosarcomas.
  • The tumours predominantly involved the upper one third; 16 were of Stage IIB.
  • Neo-adjuvant and adjuvant chemotherapy were given to all patients with osteosarcoma and Ewing's sarcoma.
  • [MeSH-minor] Adolescent. Adult. Child. Chondrosarcoma / mortality. Chondrosarcoma / pathology. Chondrosarcoma / surgery. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Neoplasm Staging. Osteosarcoma / mortality. Osteosarcoma / pathology. Osteosarcoma / surgery. Retrospective Studies. Risk Assessment. Sarcoma, Ewing / mortality. Sarcoma, Ewing / pathology. Sarcoma, Ewing / surgery. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 1977 Jun;(125):173-6 [267531.001]
  • [Cites] J Bone Joint Surg Am. 1984 Feb;66(2):306-10 [6363419.001]
  • [Cites] Clin Orthop Relat Res. 1984 Jun;(186):172-81 [6723139.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):9-24 [3456859.001]
  • [Cites] Acta Orthop Scand. 1986 Aug;57(4):290-4 [3538754.001]
  • [Cites] J Bone Joint Surg Br. 1994 Jul;76(4):559-62 [8027140.001]
  • [Cites] Orthop Clin North Am. 1989 Jul;20(3):487-503 [2662118.001]
  • [Cites] J Bone Joint Surg Am. 1991 Apr;73(4):575-83 [2013596.001]
  • [Cites] Clin Orthop Relat Res. 1992 Jun;(279):223-8 [1600659.001]
  • [Cites] Clin Orthop Relat Res. 1993 Jan;(286):241-6 [8425352.001]
  • [Cites] J Bone Joint Surg Am. 1988 Feb;70(2):307-10 [3277972.001]
  • (PMID = 15338200.001).
  • [ISSN] 0341-2695
  • [Journal-full-title] International orthopaedics
  • [ISO-abbreviation] Int Orthop
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3456982
  •  go-up   go-down


32. Tunn PU, Schmidt-Peter P, Pomraenke D, Hohenberger P: Osteosarcoma in children: long-term functional analysis. Clin Orthop Relat Res; 2004 Apr;(421):212-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma in children: long-term functional analysis.
  • Multimodal, limb-saving therapy is the treatment of choice in children with osteosarcoma.
  • Seventy-eight children treated for Stage II-B osteosarcoma who were treated between 1970 and 1997 were evaluated.
  • The most recent cohort of patients who had tumor resection combined with preoperative and postoperative chemotherapy had the best 10-year survival rate at 70%.
  • Thirty-four children (44%) were treated by limb-sparing therapy with 25 children requiring an endoprosthesis.
  • Best results were observed in children with an endoprosthesis of the distal femur who achieved as much as 90% ability to do their daily life routine.
  • Limb-saving therapy in children with osteosarcoma enables a return to activities of daily living in long-term survivors with a minimum of remaining disability.
  • [MeSH-major] Bone Neoplasms / surgery. Osteosarcoma / surgery. Recovery of Function / physiology
  • [MeSH-minor] Activities of Daily Living. Adolescent. Chemotherapy, Adjuvant. Child. Disability Evaluation. Female. Follow-Up Studies. Humans. Humerus / pathology. Humerus / physiopathology. Leg Bones / pathology. Leg Bones / physiopathology. Limb Salvage. Male. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15123950.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Chen W, Zhu H, Zhang L, Li K, Su H, Jin C, Zhou K, Bai J, Wu F, Wang Z: Primary bone malignancy: effective treatment with high-intensity focused ultrasound ablation. Radiology; 2010 Jun;255(3):967-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bone malignancy: effective treatment with high-intensity focused ultrasound ablation.
  • From December 1997 to November 2004, 80 patients with a primary bone malignancy-60 with stage IIb disease and 20 with stage III disease (Enneking staging system)-were treated with US-guided high-intensity focused ultrasound ablation.
  • High-intensity focused ultrasound ablation combined with chemotherapy was performed in 62 patients with osteosarcoma, one patient with periosteal osteosarcoma, and three patients with Ewing sarcoma.
  • The remaining 14 patients had chondrosarcoma, giant cell bone cancer, periosteal sarcoma, or an unknown malignancy and were treated with high-intensity focused ultrasound ablation only.
  • Magnetic resonance (MR) imaging or computed tomography (CT), and single photon emission computed tomography (SPECT) were used to assess tumor response.
  • RESULTS: High-intensity focused ultrasound ablation guided by real-time US was performed.
  • Survival rates at 1, 2, 3, 4, and 5 years were 93.3%, 82.4%, 75.0%, 63.7%, and 63.7%, respectively, in the patients with stage IIb cancer and 79.2%, 42.2%, 21.1%, 15.8%, and 15.8%, respectively, in those with stage III disease.
  • Among the patients with stage IIb disease, long-term survival rates were substantially improved in the 30 patients who received the full treatment-that is, complete high-intensity focused ultrasound and full cycles of chemotherapy-compared with the survival rates for the 24 patients who did not finish the chemotherapy cycles and the six patients who underwent partial ablation only.
  • [MeSH-major] Bone Neoplasms / therapy. Ultrasonic Therapy / methods. Ultrasonography, Interventional
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease Progression. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Prospective Studies. Survival Rate. Tomography, Emission-Computed, Single-Photon. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright RSNA, 2010
  • (PMID = 20501734.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


34. Ozger H, Bulbul M, Eralp L: Complications of limb salvage surgery in childhood tumors and recommended solutions. Strategies Trauma Limb Reconstr; 2010 Apr;5(1):11-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bone and soft tissue malignancies are associated with serious diagnostic and therapeutic problems in every level of pubertal growth in children.
  • Current treatment modality preferred in bone and soft tissue tumors is wide resection of tumor followed by the reconstruction of consequent defect by various methods.
  • Chemotherapy and radiotherapy are applied for systemic effects to the patient pre- and post-operatively and for local effects that facilitate the surgical procedure.
  • In this study, our aim is to discuss the problems encountered in different resection and reconstruction approaches in childhood bone and soft tissue tumors, and the recommended solutions addressed to these problems.
  • 85.3% of patients were diagnosed as osteosarcoma and the rest was Ewing's sarcoma.
  • Seventy-five percent of patients had stage IIB disease.
  • The lesions of 34 patients were detected to be in distal femur, 26 in proximal tibia and fibula, 4 in foot and ankle joint, and the remaining 4 in pelvis.
  • Limb salvage surgery has been considered as the gold standard treatment in orthopedic oncological surgery.
  • More understanding of the biology of sarcoma, introduction of new effective chemotherapeutic agents, development of new techniques concerning the surgical resection, advances in diagnostic methods, and improvements in reconstructive surgery all make a major contribution to limb salvage surgery.
  • Since some problems are still encountered, we offer a therapeutic algorithm for complications in the management of childhood tumors that we have encountered so far.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Control. 2001 Jul-Aug;8(4):344-8 [11483888.001]
  • [Cites] World J Surg Oncol. 2004;2:22 [15230975.001]
  • [Cites] Oncologist. 2006 May;11(5):503-19 [16720851.001]
  • [Cites] J Bone Joint Surg Br. 2006 Jan;88(1):95-9 [16365128.001]
  • [Cites] J Am Acad Orthop Surg. 2005 Dec;13(8):544-54 [16330516.001]
  • [Cites] J Bone Joint Surg Am. 2005 Nov;87(11):2449-55 [16264120.001]
  • [Cites] Acta Orthop Scand. 2002 Jan;73(1):85-8 [11928918.001]
  • [Cites] Croat Med J. 2004 Dec;45(6):740-5 [15578809.001]
  • [Cites] N Engl J Med. 1999 Jul 29;341(5):342-52 [10423470.001]
  • [Cites] J Bone Joint Surg Br. 1995 Mar;77(2):173-4 [7706326.001]
  • [Cites] Clin Orthop Relat Res. 1989 Oct;(247):67-73 [2676306.001]
  • [Cites] Clin Orthop Relat Res. 2003 Oct;(415):72-81 [14612632.001]
  • [Cites] Clin Orthop Relat Res. 2005 Sep;438:51-9 [16131869.001]
  • (PMID = 19957110.001).
  • [ISSN] 1828-8928
  • [Journal-full-title] Strategies in trauma and limb reconstruction (Online)
  • [ISO-abbreviation] Strategies Trauma Limb Reconstr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2839316
  •  go-up   go-down






Advertisement